A Multicenter, Open-label, Single-arm, Expanded Access Protocol of Sotorasib for the Treatment of Subjects With Previously Treated Locally Advanced Unresectable/Metastatic NSCLC With KRAS p.G12C Mutation
A Multicenter, Open-label, Single-arm, Expanded Access Protocol of Sotorasib for the Treatment of Subjects With Previously Treated Locally Advanced Unresectable/Metastatic NSCLC With KRAS p.G12C Mutation
The primary objective of this study is to provide expanded access to and characterize the safety profile of Sotorasib in participants with previously treated locally advanced/unresectable/metastatic non small-cell lung cancer (NSCLC) with KRAS p.G12C mutation in a real-world setting.
Inclusion Criteria
Exclusion Criteria
Winston-Salem, North Carolina 27157, United States
Capital Federal, Buenos Aires C1426ANZ, Argentina
Ciudad Autonoma de Buenos Aires, Buenos Aires C1118AAT, Argentina
Ciudad Autonoma de Buenos Aires, Buenos Aires C1431FWO, Argentina
Rio de Janeiro/RJ, 22250-905, Brazil
Taipei, Taipei 10002, Taiwan
Taipei, Taipei 11217, Taiwan